Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study

Authors: Linbo Wang, Zhinong Jiang, Meihua Sui, Jianguo Shen, Chaoyang Xu, Weimin Fan

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Preoperative chemotherapy (PCT) has become the standard of care in locally advanced breast cancer. The identification of patient-specific tumor characteristics that can improve the ability to predict response to therapy would help optimize treatment, improve treatment outcomes, and avoid unnecessary exposure to potential toxicities. This study is to determine whether selected biomarkers could predict pathologic response (PR) of breast tumors to three different PCT regimens, and to identify a subset of patients who would benefit from a given type of treatment.

Methods

118 patients with primary breast tumor were identified and three PCT regimens including DEC (docetaxel+epirubicin+cyclophosphamide), VFC (vinorelbine/vincristine+5-fluorouracil+cyclophosphamide) and EFC (epirubicin+5-fluorouracil+cyclophosphamide) were investigated. Expression of steroid receptors, HER2, P-gp, MRP, GST-pi and Topo-II was evaluated by immunohistochemical scoring on tumor tissues obtained before and after PCT. The PR of breast carcinoma was graded according to Sataloff's classification. Chi square test, logistic regression and Cochran-Mantel-Haenszel assay were performed to determine the association between biomarkers and PR, as well as the effectiveness of each regimen on induction of PR.

Results

There was a clear-cut correlation between the expression of ER and decreased PR to PCT in all three different regimens (p < 0.05). HER2 expression is significantly associated with increased PR in DEC regimen (p < 0.05), but not predictive for PR in EFC and VFC groups. No significant correlation was found between biomarkers PgR, Topo-II, P-gp, MRP or GST-pi and PR to any tested PCT regimen. After adjusted by a stratification variable of ER or HER2, DEC regimen was more effective in inducing PR in comparison with VFC and EFC regimens.

Conclusion

ER is an independent predictive factor for PR to PCT regimens including DEC, VFC and EFC in primary breast tumors, while HER2 is only predictive for DEC regimen. Expression of PgR, Topo-II, P-gp, MRP and GST-pi are not predictive for PR to any PCT regimens investigated. Results obtained in this clinical study may be helpful for the selection of appropriate treatments for breast cancer patients.
Appendix
Available only for authorised users
Literature
1.
Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP: Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008, 26: 814-819. 10.1200/JCO.2007.15.3510.CrossRefPubMed
2.
Buzdar AU: Preoperative chemotherapy treatment of breast cancer-a review. Cancer. 2007, 110: 2394-2407. 10.1002/cncr.23083.CrossRefPubMed
3.
Subramaniam DS, Isaacs C: Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol. 2005, 6: 147-159. 10.1007/s11864-005-0022-1.CrossRefPubMed
4.
Schmid P, Wischnewsky MB, Sezer O, Böhm R, Possinger K: Prediction of response to hormonal treatment in metastatic breast cancer. Oncology. 2002, 63: 309-316. 10.1159/000066224.CrossRefPubMed
5.
Horwitz KB, McGuire WL: Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science. 1975, 189: 726-727. 10.1126/science.168640.CrossRefPubMed
6.
Low SC, Dixon AR, Bell J, Ellis IO, Elston CW, Robertson JF, Blamey RW: Tumour oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment. Br J Surg. 1992, 79: 1314-1316. 10.1002/bjs.1800791224.CrossRefPubMed
7.
Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD: Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol. 2002, 20: 2319-2326. 10.1200/JCO.2002.08.125.CrossRefPubMed
8.
Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, Vijver van de MJ: Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 2003, 88: 406-412. 10.1038/sj.bjc.6600749.CrossRefPubMedPubMedCentral
9.
Chhieng DC, Rodriguez-Burford C, Meleth S, Grizzle WE, Ferguson SM: Assessment of biomarker expression in predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Breast J. 2007, 13: 534-535. 10.1111/j.1524-4741.2007.00483.x.CrossRefPubMed
10.
Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L: p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res. 2000, 6: 2751-2758.PubMed
11.
Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997, 3: 593-600.PubMed
12.
Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999, 17: 460-469.PubMed
13.
Tomczykowski J, Szubstarski F, Kurylcio L, Stanislawek A, Barycki J, Baranowski W: Does the degree of cell lesion in breast cancer after inductive chemotherapy have any prognostic value?. Acta Oncol. 1999, 38: 949-953. 10.1080/028418699432644.CrossRefPubMed
14.
Katzenellenbogen BS: Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways. J Soc Gynecol Investig. 2000, 7 (1 Suppl): S33-37. 10.1016/S1071-5576(99)00058-1.CrossRefPubMed
15.
Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V: The 17q12-q21 amplification: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat Rev. 2007, 33: 64-77. 10.1016/j.ctrv.2006.10.001.CrossRefPubMed
16.
Volm M: Multidrug resistance and its reversal. Anticancer Res. 1998, 18 (4C): 2905-2917.PubMed
17.
Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995, 180: 297-306.PubMed
18.
Sui M, Chen F, Chen Z, Fan W: Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer. 2006, 119: 712-717. 10.1002/ijc.21743.CrossRefPubMed
19.
Kang SP, Martel M, Harris LN: Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol. 2008, 20: 40-46. 10.1097/GCO.0b013e3282f40de9.CrossRefPubMed
20.
Chintamani , Singh JP, Mittal MK, Saxena S, Bansal A, Bhatia A, Kulshreshtha P: Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer–a prospective clinical study. World J Surg Oncol. 2005, 3: 61-10.1186/1477-7819-3-61.CrossRefPubMedPubMedCentral
21.
Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med. 1978, 299: 1330-1334.CrossRefPubMed
22.
Colleoni M, Minchella I, Mazzarol G, Nolè F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, Curigliano G, Veronesi P, Intra M, Goldhirsch A: Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol. 2000, 11: 1057-1059. 10.1023/A:1008334404825.CrossRefPubMed
23.
Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006, 295 (14): 1658-1667. 10.1001/jama.295.14.1658.CrossRefPubMedPubMedCentral
24.
MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM: Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer. 1996, 74: 1458-1465.CrossRefPubMedPubMedCentral
25.
Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF: A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res. 2003, 9 (1): 124-133.PubMed
26.
Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med. 1978, 298: 1223-1228.CrossRefPubMed
27.
Sui M, Huang Y, Park BH, Davidson NE, Fan W: Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 2007, 67: 5337-5344. 10.1158/0008-5472.CAN-06-4582.CrossRefPubMed
28.
Gapinski PV, Donegan WL: Estrogen receptors and breast cancer: prognostic and therapeutic implications. Surgery. 1980, 88: 386-393.PubMed
29.
Hilf R, Feldstein ML, Gibson SL, Savlov ED: The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer. 1980, 45: 1993-2000. 10.1002/1097-0142(19800415)45:8<1993::AID-CNCR2820450802>3.0.CO;2-2.CrossRefPubMed
30.
Hilf R, Feldstein ML, Savlov ED, Gibson SL, Seneca B: The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer. 1980, 46 (12 Suppl): 2797-2800. 10.1002/1097-0142(19801215)46:12+<2797::AID-CNCR2820461411>3.0.CO;2-B.CrossRefPubMed
31.
Minisini AM, Di Loreto C, Mansutti M, Artico D, Pizzolitto S, Piga A, Puglisi F: Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer. Cancer Lett. 2005, 224 (1): 133-139.CrossRefPubMed
32.
Graham JD, Clarke CL: Physiological action of progesterone in target tissues. Endocr Rev. 1997, 18: 502-519. 10.1210/er.18.4.502.PubMed
33.
Bouchard P: Progesterone and the progesterone receptor. J Reprod Med. 1999, 44 (2 Suppl): 153-157.PubMed
34.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN: Targeted therapy in breast cancer: the HER2/neu gene and protein. Mol Cell Proteomics. 2004, 3: 379-398. 10.1074/mcp.R400001-MCP200.CrossRefPubMed
35.
Traina A, Agostara B, Marasà L, Calabrò M, Zarcone M, Carruba G: HER2/neu expression in relation to clinicopathologic features of breast cancer patients. Ann N Y Acad Sci. 2006, 1089: 159-167. 10.1196/annals.1386.029.CrossRefPubMed
36.
Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG: HER2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer. 2007, 7: 36-10.1186/1471-2407-7-36.CrossRefPubMedPubMedCentral
37.
Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 2007, 16: 86-93. 10.1016/j.breast.2006.06.008.CrossRefPubMed
38.
Warm M, Kates R, Mallmann P, Dick M, Nawroth F, Harbeck N, Paepke S, Thomas A: Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer. Anticancer Res. 2007, 27: 1031-1038.PubMed
39.
Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ: The effect of HER2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 1997, 15: 537-547. 10.1038/sj.onc.1201222.CrossRefPubMed
40.
Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008, 26: 1275-1281. 10.1200/JCO.2007.14.4147.CrossRefPubMed
41.
Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer. 2007, 7: 203-10.1186/1471-2407-7-203.CrossRefPubMedPubMedCentral
42.
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007, 13: 2329-2334. 10.1158/1078-0432.CCR-06-1109.CrossRefPubMed
43.
Gurbuxani S, Zhou D, Simonin G, Raina V, Arya LS, Sazawal S, Marie JP, Bhargava M: Expression of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India. Ann Hematol. 1998, 76: 195-200. 10.1007/s002770050388.CrossRefPubMed
44.
Galimberti S, Testi R, Guerrini F, Fazzi R, Petrini M: The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia. J Chemother. 2003, 15: 374-379.PubMed
45.
Chintamani , Singh JP, Mittal MK, Saxena S, Bansal A, Bhatia A, Kulshreshtha P: Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer–a prospective clinical study. World J Surg Oncol. 2005, 3: 61-10.1186/1477-7819-3-61.CrossRefPubMedPubMedCentral
46.
Koh EH, Chung HC, Lee KB, Lim HY, Kim JH, Roh JK, Min JS, Lee KS, Kim BS: The value of immunohistochemical detection of P-glycoprotein in breast cancer before and after induction chemotherapy. Yonsei Med J. 1992, 33: 137-142.CrossRefPubMed
47.
Seymour L, Bezwoda WR, Dansey RD: P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Breast Cancer Res Treat. 1995, 36: 61-69. 10.1007/BF00690186.CrossRefPubMed
48.
MacGrogan G, Rudolph P, Mascarel Id I, Mauriac L, Durand M, Avril A, Dilhuydy JM, Robert J, Mathoulin-Pélissier S, Picot V, Floquet A, Sierankowski G, Coindre JM: DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer. 2003, 89: 666-671. 10.1038/sj.bjc.6601185.CrossRefPubMedPubMedCentral
49.
Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D: Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther. 2004, 3: 1207-1214.PubMed
50.
Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, Sotiriou C, Renard N, Richard V, Piccart MJ, Di Leo A: Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol. 2004, 24: 201-209.PubMed
51.
Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson NO, Söderberg M, Saksela E, Blomqvist C: TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol. 2006, 45: 590-596. 10.1080/02841860500543182.CrossRefPubMed
Metadata
Title
The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study
Authors
Linbo Wang
Zhinong Jiang
Meihua Sui
Jianguo Shen
Chaoyang Xu
Weimin Fan
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-226

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

CYP17, GSTP1, PON1 and GLO1gene polymorphisms as risk factors for breast cancer: an Italian case-control study

Research article

Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection

Research article

The role of PET/CT in detection of gastric cancer recurrence

Research article

Do serum biomarkers really measure breast cancer?

Research article

Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO

Research article

Gene expression profiling of alveolar soft-part sarcoma (ASPS)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits